RU2003112013A - LACTIC-ACID BACTERIA REDUCING THE TENDENCY TO MANIFESTATION OF ALLERGIC REACTIONS - Google Patents

LACTIC-ACID BACTERIA REDUCING THE TENDENCY TO MANIFESTATION OF ALLERGIC REACTIONS

Info

Publication number
RU2003112013A
RU2003112013A RU2003112013/13A RU2003112013A RU2003112013A RU 2003112013 A RU2003112013 A RU 2003112013A RU 2003112013/13 A RU2003112013/13 A RU 2003112013/13A RU 2003112013 A RU2003112013 A RU 2003112013A RU 2003112013 A RU2003112013 A RU 2003112013A
Authority
RU
Russia
Prior art keywords
bacterial strain
food
strain according
supernatant
polypeptide
Prior art date
Application number
RU2003112013/13A
Other languages
Russian (ru)
Other versions
RU2294366C2 (en
Inventor
Жак Эдуар ЖЕРМОН
Блэз КОРТЕЗИ
Беат МОЛЛЕ
Родольф ФРИЦШЕ
Original Assignee
Сосьете Де Продюи Нестле С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сосьете Де Продюи Нестле С.А. filed Critical Сосьете Де Продюи Нестле С.А.
Publication of RU2003112013A publication Critical patent/RU2003112013A/en
Application granted granted Critical
Publication of RU2294366C2 publication Critical patent/RU2294366C2/en

Links

Claims (13)

1. Бактериальный штамм молочно-кислых бактерий, экспрессирующий на поверхности клеток полипептид, включающий толерогенный пептид гетерологичный указанному полипептиду, в результате чего пептид приобретает устойчивость к деградации под воздействием ферментов желудка/двенадцатиперстной кишки, сохраняет свои толерогенные свойства и проявляется на периферии полипептида.1. A bacterial strain of lactic acid bacteria expressing a polypeptide on the cell surface, including a tolerogenic peptide heterologous to the specified polypeptide, as a result of which the peptide becomes resistant to degradation under the influence of gastric / duodenal enzymes, retains its tolerogenic properties and appears at the periphery of the polypeptide. 2. Бактериальный штамм по п.1, который выбирают из Lactobacillus или Bifidobacterium.2. The bacterial strain according to claim 1, which is selected from Lactobacillus or Bifidobacterium. 3. Бактериальный штамм по п.1 или 2, в котором толерогенный пептид происходит из пищевого продукта.3. The bacterial strain according to claim 1 or 2, in which the tolerogenic peptide comes from a food product. 4. Пищевая композиция, включающая бактериальный штамм по любому из пп.1-3 или его супернатант.4. A food composition comprising a bacterial strain according to any one of claims 1 to 3 or its supernatant. 5. Пищевая композиция по п.4, которую выбирают из группы, состоящей из молока, йогурта, творога, сыра, кисломолочных продуктов, ферментированных продуктов на основе молока, мороженного, ферментированных продуктов на основе злаковых, продуктов на основе сухого молока, детского питания и корма для домашних животных.5. The food composition according to claim 4, which is selected from the group consisting of milk, yogurt, cottage cheese, cheese, dairy products, fermented products based on milk, ice cream, fermented products based on cereals, products based on dried milk, baby food and pet food. 6. Пищевая композиция по п.4 или 5, в которой бактериальный штамм содержится в количестве 107-1011 cfu/дозированную упаковку.6. The food composition according to claim 4 or 5, in which the bacterial strain is contained in an amount of 10 7 -10 11 cfu / unit dose. 7. Фармацевтическая композиция, включающая бактериальный штамм по любому из пп.1-3 или его супернатант.7. A pharmaceutical composition comprising a bacterial strain according to any one of claims 1 to 3 or its supernatant. 8. Фармацевтическая композиция по п.8, в которой бактериальный штамм содержится в количестве 1010-1012 cfu/дозированную форму.8. The pharmaceutical composition of claim 8, in which the bacterial strain is contained in an amount of 10 10 -10 12 cfu / dosage form. 9. Применение бактериального штамма по любому из пп.1-3 или его супернатанта для получения орально вводимого носителя для лечения аллергии.9. The use of a bacterial strain according to any one of claims 1 to 3 or its supernatant to obtain an orally administered carrier for the treatment of allergies. 10. Применение пищевой или фармацевтической композиции по любому из пп.1-9, для получения орально вводимого носителя, предназначенного для лечения аллергии.10. The use of a food or pharmaceutical composition according to any one of claims 1 to 9, to obtain an orally administered carrier intended for the treatment of allergies. 11. Применение по п.10, в котором композицию вводят перорально или назально.11. The use of claim 10, in which the composition is administered orally or nasally. 12. Вакцина, включающая бактериальный штамм по любому из пп.1-3 или его фракции.12. A vaccine comprising a bacterial strain according to any one of claims 1 to 3 or its fractions. 13. Вакцина по п.13, включающая мембранную фракцию лизированных бактерий.13. The vaccine according to item 13, including the membrane fraction of lysed bacteria.
RU2003112013/13A 2000-09-25 2001-09-21 Transformed lactic-acid bacteria reducing susceptibility to allergic reactions and uses thereof RU2294366C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00120867 2000-09-25
EP00120867.7 2000-09-25

Publications (2)

Publication Number Publication Date
RU2003112013A true RU2003112013A (en) 2004-12-10
RU2294366C2 RU2294366C2 (en) 2007-02-27

Family

ID=8169939

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003112013/13A RU2294366C2 (en) 2000-09-25 2001-09-21 Transformed lactic-acid bacteria reducing susceptibility to allergic reactions and uses thereof

Country Status (21)

Country Link
US (1) US7498162B2 (en)
EP (1) EP1379635A2 (en)
JP (1) JP2004514424A (en)
KR (1) KR20030034178A (en)
CN (1) CN1246456C (en)
AR (1) AR033574A1 (en)
AU (2) AU2056102A (en)
BG (1) BG107657A (en)
BR (1) BR0114105A (en)
CA (1) CA2420160A1 (en)
CZ (1) CZ2003749A3 (en)
HU (1) HUP0302585A3 (en)
IL (1) IL154284A0 (en)
MX (1) MXPA03001673A (en)
NO (1) NO20031159L (en)
NZ (1) NZ524527A (en)
PL (1) PL365246A1 (en)
RU (1) RU2294366C2 (en)
SK (1) SK3642003A3 (en)
WO (1) WO2002024883A2 (en)
ZA (1) ZA200301244B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
EP1319410A1 (en) * 2001-12-11 2003-06-18 Société des Produits Nestlé S.A. Use of micro-organisms for a directed delivery of substances to specific parts of the gut
AU2003236156A1 (en) * 2003-04-24 2005-01-04 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
JP2008523116A (en) * 2004-12-14 2008-07-03 アルカベロ アクチェセルスカプ Pharmaceutical composition comprising bacterial cells displaying heterologous protein compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
PL1885383T3 (en) 2005-05-31 2017-06-30 Iams Europe B.V. Feline probiotic bifidobacteria
EP2003989A1 (en) * 2006-03-31 2008-12-24 DSMIP Assets B.V. Process for the hydrolysis of milk proteins
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
MX2011007912A (en) * 2009-01-27 2011-09-06 Arla Foods Amba Long shelf life milk and milk-related products, and a process and milk processing plant for their manufacture.
CN102802648A (en) * 2009-05-11 2012-11-28 雀巢产品技术援助有限公司 Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EP3338565A1 (en) * 2010-06-04 2018-06-27 N.V. Nutricia Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins
EP2751573B1 (en) * 2011-09-02 2017-11-08 DH Technologies Development Pte. Ltd. System and method for the detection of ovalbumin
WO2013083140A1 (en) * 2011-12-07 2013-06-13 N.V. Nutricia Beta-lactoglobulin peptides for treating cow's milk protein allergy
WO2016148562A1 (en) * 2015-03-18 2016-09-22 N.V. Nutricia Method for inducing oral tolerance via administration of beta-lactoglobulin derived peptide in combination with probiotic
CN105362296A (en) * 2015-11-27 2016-03-02 成都吉氧屋科技有限公司 Lactic acid bacteria nasal wash
WO2019212330A1 (en) * 2018-04-30 2019-11-07 N.V. Nutricia Formula with a specific beta-lactoglobulin peptide
WO2019212329A1 (en) * 2018-04-30 2019-11-07 N.V. Nutricia Formula with specific beta-lactoglobulin peptides
CN114149486B (en) * 2021-05-28 2023-05-12 中国科学院大连化学物理研究所 Antibacterial peptide MAMP-01 and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302855D0 (en) * 1993-09-06 1993-09-06 Martin Lindberg Method and means for producing plasma proteinase inhibitor binding proteins
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
AU2149495A (en) * 1995-04-11 1996-10-30 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface
FI104465B (en) 1995-06-14 2000-02-15 Valio Oy Protein hydrolyzates for the treatment and prevention of allergies and their preparation and use
GB9518323D0 (en) 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
MY129566A (en) * 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance

Similar Documents

Publication Publication Date Title
RU2003112013A (en) LACTIC-ACID BACTERIA REDUCING THE TENDENCY TO MANIFESTATION OF ALLERGIC REACTIONS
Widyastuti et al. Health-promoting properties of lactobacilli in fermented dairy products
Goldin Health benefits of probiotics
Fooks et al. Probiotics as modulators of the gut flora
RU2003129265A (en) LACTIC-ACID BACTERIA AS AN AGENT FOR THE TREATMENT AND PREVENTION OF ALLERGIES
Tamime et al. Production and maintenance of viability of probiotic microorganisms in dairy products
Kalantzopoulos Fermented products with probiotic qualities
RU2748839C2 (en) Compositions, methods and kits for stimulating the mucosal immune system
AU2008333718B2 (en) Probiotic bacteria and regulation of fat storage
EP1034787A1 (en) Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
JP2002537865A5 (en)
JP2008214253A (en) Visceral fat reduction agent
Kitazawa et al. Interferon induction in murine peritoneal macrophage by stimulation with Lactobacillus acidophilus
US10925906B2 (en) Composition for improving brain function for neonates
KR20040018375A (en) Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
Umer Khan Probiotics in dairy foods: a review
Sarkar Effect of probiotics on biotechnological characteristics of yoghurt: A review
US20100203026A1 (en) Probiotics for inducing satiety and/or satiation
Tesfaye et al. Dairy and nondairy-based beverages as a vehicle for probiotics, prebiotics, and symbiotics: Alternatives to health versus disease binomial approach through food
WO2009007515A1 (en) Lactic acid bacteria having pro-inflammatory characteristics
Yıldız Overview of yogurt and other fermented dairy products
CN103918795A (en) Tea polyphenols probiotics goat milk tablet and preparation method thereof
Mudgal et al. Dahi—An Indian naturally fermented yogurt
WO2018012578A1 (en) Ghrelin secretion promotor
Kaur et al. Role of fermented dairy foods in human health